Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CABOZANTINIB S-MALATE Cause Prostate cancer? 8 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Prostate cancer have been filed in association with CABOZANTINIB S-MALATE (CABOMETYX). This represents 0.0% of all adverse event reports for CABOZANTINIB S-MALATE.

8
Reports of Prostate cancer with CABOZANTINIB S-MALATE
0.0%
of all CABOZANTINIB S-MALATE reports
3
Deaths
1
Hospitalizations

How Dangerous Is Prostate cancer From CABOZANTINIB S-MALATE?

Of the 8 reports, 3 (37.5%) resulted in death, 1 (12.5%) required hospitalization.

Is Prostate cancer Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB S-MALATE. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does CABOZANTINIB S-MALATE Cause?

Diarrhoea (8,282) Fatigue (6,819) Off label use (5,245) Nausea (4,341) Decreased appetite (4,076) Blood pressure increased (2,939) Malignant neoplasm progression (2,718) Palmar-plantar erythrodysaesthesia syndrome (2,706) Weight decreased (2,657) Stomatitis (2,560)

What Other Drugs Cause Prostate cancer?

RANITIDINE (60,641) LEUPROLIDE (1,736) ABIRATERONE (661) ENZALUTAMIDE (642) ADALIMUMAB (573) ETANERCEPT (482) METHOTREXATE (444) INFLIXIMAB (376) LENALIDOMIDE (366) PREDNISONE (317)

Which CABOZANTINIB S-MALATE Alternatives Have Lower Prostate cancer Risk?

CABOZANTINIB S-MALATE vs CAFFEINE CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL CABOZANTINIB S-MALATE vs CALASPARGASE PEGOL-MKNL CABOZANTINIB S-MALATE vs CALCIFEDIOL CABOZANTINIB S-MALATE vs CALCIPOTRIENE

Related Pages

CABOZANTINIB S-MALATE Full Profile All Prostate cancer Reports All Drugs Causing Prostate cancer CABOZANTINIB S-MALATE Demographics